Inventor

BOTSTEIN DAVID

US57 patents

⚠️ This page may combine multiple inventors who share the name “BOTSTEIN DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BOTSTEIN DAVID

GENENTECH INC

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Nucleic acids encoding PRO189 polypeptides

Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides nucleic acid encoding

Nucleic acid encoding PRO211 polypeptides

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Tissue plasminogen activator having zymogenic or fibrin specific properties

Antibodies to DcR3 Polypeptide, a TNFR Homolog

Anti-PRO1558 antibodies

PRO853 nucleic acids

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Tissue plasminogen activator having zymogenic or fibrin specific properties

Tissue plasminogen activator having zymogenic or fibrin specific properties

Tissue plasminogen activator having zymogenic properties

Method for identifying tissue plasminogen activator having zymogenic or fibrin specific properties

Tissue plasminogen activator having zymogenic or fibrin specific properties

Methods for modifying DNA and for detecting effects of such modification on interaction of encoded modified polypeptides with target substrates

PRO363 polypeptides

PRO347 nucleic acids

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Tussue plasminogen activator having zymogenic or fibrin specific properties

Tissue plasminogen activator having zymogenic or fibrin specific properties

NL4 tie ligand homologue

NL4 tie ligand homologue nucleic acid

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Anti-PRO1347 antibodies

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Method of inducing fetal hemoglobin synthesis

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Cardiotrophin-1 defective mouse

Tissue plasminogen activator having zymogenic or fibrin specific properties

Tissue plasminogen activator having zymogenic or fibrin specific properties

Secreted and transmembrane polypeptides and nucleic acids encoding the same

WISP polypeptides and nucleic acids encoding same

Cardiotrophin-1 compositions and methods for the treatment of tumor

Nucleic acids encoding PRO830

COLLABORATIVE RES INC

Use of the GAL1 yeast promoter

GAL1 yeast promoter linked to non galactokinase gene

Rennin-containing disrupted yeast cells used in cheese manufacture

LEVY RONALD

Classification of patients having diffuse large B-cell lymphoma based upon gene expression

UNIV LELAND STANFORD JUNIOR

Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors